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Inapopulation-basedcase-controlstudy,weexploredtheassociationsbetween42polymorphismsinsevengenesinthisregionand
non-smallcelllungcancer(NSCLC)riskamongCaucasian(364cases;380controls)andAfricanAmerican(95cases;103controls)
women. Two TERT region SNPs, rs2075786 and rs2853677, conferred an increased risk of developing NSCLC, especially among
African American women, and TERT-rs2735940 was associated with a decreased risk of lung cancer among African Americans.
Five of the 20 GHR polymorphisms and SEPP1-rs6413428 were associated with a marginally increased risk of NSCLC among
Caucasians.RandomforestanalysisreinforcedtheimportanceofGHRamongCaucasiansandidentiﬁedAMACR,TERT,andGHR
amongAfrican Americans, which were also signiﬁcant usinggene-based risk scores. Smoking-SNP interactions were explored, and
haplotypes in TERT and GHR associated with NSCLC risk were identiﬁed. The roles of T E R T ,G H R ,A M A C Rand SEPP1 genes in
lung carcinogenesis warrant further exploration.
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1.Introduction
As lung cancer is the second most commonly diagnosed
cancer in the United States and the leading cause of cancer
related mortality, ﬁnding markers associated with risk is
vital to early detection and discovery of novel chemopre-
ventive agents [1]. Recently published studies by Wang et al.
(2008) and Rafner et al. (2009) indicate that one such genetic
region associated with lung cancer risk is the short arm
of chromosome 5 near CLPTM1L and including SLC6A19,
SLC6A18, TERT,a n dSLC6A3 [2, 3]. Gene ampliﬁcation
in this region of chromosome 5p was also identiﬁed
through a ﬂuorescence in situ hybridization study of lung
tumors compared to normal lung tissue from controls
[4].
Atleastoneofthegenesinthisregion,telomerasereverse
transcriptase (TERT), has been explored in relation to lung
tumorigenesis. TERT codes for the catalytic subunit of
telomerase, an enzyme complex that adds TTAGGG telom-
eric repeats, ensuring chromosomal stability and allowing
cells to avert senescence. Independent of telomere elonga-
tion, TERT expression also has been linked to mobilization
and proliferation of epidermal stem cells and increased sus-
ceptibility to tumorigenesis in mouse models [5]. Observed
in approximately 80% of lung tumor cells, telomerase is
not normally expressed in somatic cells that are mitotically
inactive [6]. While cellular immortalization does not con-
fer transformation, it may be one step in tumorigenesis.
Approximately 67%–80% of NSCLC patients express TERT
in tumor tissue but not adjacent, nonneoplastic lung tissue
[7–9], and telomerase activity is positively associated with
TERT expression[10].LevelofTERT expressionisassociated
with lymph node metastasis but not grade among NSCLC
patients [9].2 Journal of Cancer Epidemiology
Another gene in this region, SLC6A3, codes for the
dopamine transporter gene. A variable number tandem
repeat (VNTR) in this gene has been associated with
enhanced transcription of the dopamine transporter, which
is responsible for dopamine reuptake, and with stronger
cue-induced smoking cravings as well as decreased smoking
cessation [11, 12]. In addition to its eﬀects on smoking
cravings, dopamine has been reported to play a role in
lung tumorigenesis as dopamine receptors are expressed by
lung tumor cell lines [13]. Presence of the minor allele
of the SLC6A3 SNP rs6413429 has been associated with
an increased risk of lung cancer in a study of smoking
Caucasians of Norwegian origin (OR 2.46; 95% CI 1.59–
3.82) [14]. Whether these associations between dopamine
receptor genotype and lung cancer are related to smoking
behavior or an eﬀect on cellular proliferation in NSCLC
remains to be determined.
Other genes on the short arm of chromosome 5 that have
been studied in relation to lung cancer risk include MTRR,
GHR,a n dSEPP1. MTRR codes for methionine synthase
reductaseandactivatesmethioninesynthase,andtwostudies
found an interaction between smoking and MTRR genotype
in association with lung cancer risk [15, 16]. Similarly, an
interaction between smoking and a nonsynonymous GHR
SNP, Pro495Thr, which may be associated with an increased
risk of lung cancer, has been suggested [17, 18]. A role
for selenoprotein P coded by SEPP1 has been indicated
by decreased expression of SEPP1 in NSCLC tumor tissue
relative to normal lung tissue [19]. While these genes have
been studied independently, few studies have examined this
entire 5p region in its relationship with lung cancer risk or in
African Americans speciﬁcally.
We conducted a population-based case-control study
to characterize the relationships between single nucleotide
polymorphisms (SNPs) in genes in the chromosome 5p
region and risk of non-small cell lung cancer (NSCLC)
among Caucasian and African American women.
2.MaterialsandMethods
2.1. Study Population. The study population and data
collection methods have been described previously [20].
Participants were identiﬁed through the population-based
Metropolitan Detroit Cancer Surveillance System (MDCSS),
a member of the National Cancer Institute’s Surveillance,
Epidemiology, and End Results (SEER) program. Eligible
cases were women between the ages of 18 and 74 years
diagnosed with primary NSCLC in the Detroit metro area
(Wayne, Macomb, and Oakland counties) from November
1, 2001 through October 31, 2005. While ascertainment ini-
tially was focused on adenocarcinoma cases, after November
1, 2004 study eligibility was broadened to include all NSCLC
histologies. As only in-person interviews were conducted,
women deceased at ascertainment or ﬁrst contact were
not eligible. Five-hundred, seventy-seven cases completed
an interview (55%). Of the eligible cases who agreed to
participate, 459 provided a blood specimen.
Population-based controls were identiﬁed through
random-digit dialing and were frequency matched to cases
on race, county of residence, and 5-year age group. Of
the households that completed the eligibility screening
questionnaire, 575 completed an interview, and 209 women
refused participation. Included in these analyses were 483
controls who provided a blood sample.
2.2. Data Collection. All local institutional review boards
approved this study, and informed consent was obtained
from each subject prior to study participation. In-person
interviews were conducted to collect demographic informa-
tion, health history, family history, smoking history, current
body mass index (BMI), and history of medication use.
Medical history included self-report of physician diagnoses
of emphysema, chronic bronchitis, or chronic obstructive
pulmonary disease (COPD), and reports of diagnoses of
lung diseases within one year of lung cancer diagnosis (for
cases) or interview (for controls) were excluded. Emphy-
sema, COPD and chronic bronchitis were combined to
create a broad COPD variable. Family history of lung
cancer was coded yes or no based on detailed ﬁrst-degree
family history information. Smoking history included age
started and stopped smoking, years of smoking, average
number of cigarettes per day, type of cigarette, and years
of smoking interruption. Ex-smokers were women who quit
smoking more than two years prior to diagnosis/interview.
Never smokers smoked less than 100 cigarettes in their
lifetime. Medication history included regular use of aspirin,
deﬁned as taking at least one pill three times per week
or more for at least one month during a lifetime. Pill use
information collected included ages at which participants
started and stopped pill use, number of pills per week taken,
and whether baby/senior citizen aspirin (81mg) or adult-
strength aspirin (325mg) was taken. To avoid protopathic
bias, pill use one year prior to diagnosis/interview was
excluded.
2.3. Sample Collection and Genotyping. Blood specimens
were collected in Vacutainer Plus tubes containing EDTA,
and DNA was isolated from whole blood using a Qiagen
AutoPure LS Genomic DNA Puriﬁcation System (Gentra
Systems, Minneapolis, MN) following the manufacturer’s
protocols. Genomic DNA was submitted to the Wayne
State University Applied Genomics Technology center for
genotyping. The Illumina GoldenGate assay using the
Cancer SNP Panel was utilized. The panel consists of
primers to interrogate 1421 SNPs in 408 genes, includ-
ing 49 SNPs in eight genes on chromosome 5p (AHRR,
SLC6A18, TERT, SLC6A3, MTRR, AMACR, GHR,a n d
SEPP1) selected from the National Cancer Institute’s Can-
cer Genome Anatomy Project SNP500 Cancer Database
(http://snp500cancer.nci.nih.gov/home 1.cfm) The Golden-
Gate assay was run according to the manufacturer’s direc-
tions, and data were analyzed using Bead Studio software
(Illumina).
2.4. Statistical Analysis. To assess Hardy-Weinberg equilib-
rium, a χ2 goodness-of-ﬁt test was conducted for each SNP
for African American and Caucasian controls separately.Journal of Cancer Epidemiology 3
Polymorphisms with minor allele frequencies (MAFs) less
than 5% among Caucasian or African American controls
were excluded from subsequent analyses. Pearson’s χ2 test
was used to analyze allele frequency distribution diﬀerences
by race among controls; P-values were corrected for multiple
comparisons using the Benjamini and Hochberg False Dis-
covery Rate (FDR) method [21].
2.5. SNPs and Risk of NSCLC. Cases were compared to
controlsondemographicfactorsusingχ2 testsforcategorical
variables and t-tests for continuous variables. Multivariable
unconditional logistic regression models were constructed
by race adjusting for smoking pack-year history, age at
diagnosis/interview, family history of lung cancer, history
of COPD, adult aspirin use (never/ever), years of education
and BMI. Model ﬁtness was assessed by race by calcu-
lating 1 −  γ,am e a s u r eo fo v e r ﬁ t t i n g[ 22]. This model
was validated internally using a bootstrapping method
to obtain a bias-corrected Somers’ Dxy rank correlation
by race. Heterozygotes were combined with homozygous
variants in a dominant model testing for the relationship
between presence of the minor allele and risk of NSCLC
separately by race. The −log10 (P-value) was calculated
based on unadjusted P-values by race. A genetic risk score
was calculated for each gene for Caucasians and African
Americans separately by summing the product of the t-
statistic (β coeﬃcient divided by the standard error) for each
SNP and dominant model coding for the SNP (0 = wild
type; 1 = heterozygote or homozygous variant). This score
was included in an unconditional logistic regression model
adjusted for covariates to assess the statistical signiﬁcance of
thegeneasariskfactorforlungcancer.Associationsbetween
5p polymorphisms and NSCLC risk were also assessed by
race in recessive, genotypic, and log additive genetic models.
To assess the potential interaction between 5p region SNPs
and smoking history, analysis was stratiﬁed on smoking
history (never/ever) among Caucasian women only because
the number of African American women was too small for
these analyses.
As an alternative approach to assess relationships
between SNPs and NSCLC risk, random forest analysis was
also conducted by race [23]; (http://stat-www.berkeley.edu/
users/breiman/RandomForests/cc home.htm). Random for-
est analysis is a classiﬁcation method that involves boot-
strapping and a bagging algorithm. Brieﬂy, a random sample
of the dataset is taken with replacement, creating an out
of bag set of individuals for validation, and variables are
randomly sampled without replacement when growing a
tree to avoid overﬁtting. The variable that best classiﬁes
individuals based on case-control status is used to split the
dataset. A decision tree is grown in this fashion until a
stopping rule is achieved. This process is repeated a number
of times, and importance measures, including mean decrease
in accuracy scores, are produced. Unlike logistic regression
whenappliedtoSNPassociationdata,thisnonlinearmethod
takes into consideration interactions of other SNPs and
risk factors in assessment of the importance of a single
polymorphism.
All analyses were conducted using SAS v9.1.3 (SAS
Institute; Cary, NC) except for the internal validation of the
logistic model and the random forest analysis, which were
carried out in R v2.8.1. As a quality control method, data
were reclustered in BeadStudio after omitting individuals
with >10% of genotype data missing and reanalyzed.
2.6. Linkage Disequilibrium Analysis. PLINK v1.05 (Shaun
Purcell, http://pngu.mgh.harvard.edu/purcell/plink) was
used for linkage disequilibrium analysis and haplotype
construction separately by race among controls and to
analyze the association between haplotypes and lung
cancer risk in an adjusted model [24]. Haploview v4.1 was
utilized to image LD maps in the genes identiﬁed as having
associations with NSCLC risk on logistic regression and
random forest analysis for the Caucasian Europeans in
Utah (CEU) and Yoruban (YRI) populations. Associations
between TERT and GHR haplotypes and risk of NSCLC
were assessed by unconditional logistic regression by race
adjusting for covariates using the haplo.ccs package in R
[25].
2.7. SNP Functionality Analysis. The Sorting Intolerant from
Tolerant (SIFT) program was utilized to predict the relation-
ship between nonsynonymous SNPs analyzed in this study
andproteinfunction[26].SIFTscores<0.10wereconsidered
to be damaging using homologues in the protein alignment.
Median sequence information content (IC) values >3.0 are
suggestive of reduced sequence diversity and a resulting
higher chance of false positive error.
3. Results
3.1. SNPs. Of the 49 SNPs genotyped in the chromosome 5p
region, seven had a minor allele frequency <5%: SLC6A18-
rs34156553, TERT-rs13167280, SLC6A3-rs6413429, MTRR-
rs2287779, MTRR-rs2287780, AMACR-rs6863657, and
AMACR-rs3195676, leaving 42 SNPs for analysis. Five
SNPs included in the analyses were in Hardy-Weinberg
disequilibrium among either Caucasian (TERT-rs2853690,
GHR-rs2940930, GHR-rs7735889) or African American
(GHR-rs6180, SEPP1-rs6413428) controls.
3.2. Participant Characteristics. Approximately 21% of par-
ticipants were African American (Table 1). Cases of both
races were more likely than controls to report being current
smokers, having a history of COPD, having a ﬁrst degree
family history of lung cancer, having slightly fewer years
of education, and having a lower body mass index (BMI)
at the time of interview. While cases reported a higher
smoking pack-year history than controls of both races, this
diﬀerence was only statistically signiﬁcant among Caucasian
women.
3.3. Chromosome 5p SNPs, and Risk of NSCLC. Allelic
frequencies diﬀered between Caucasians and African Amer-
icans for 31 out of the 42 SNPs analyzed (Table 2), and
the minor allele diﬀered for 15 of these SNPs. Thus, all4 Journal of Cancer Epidemiology
Table 1: Participant characteristics.
Variable Caucasians African Americans
Cases Controls P-value Cases Controls P-value
N 364 380 95 103
Age (years): Mean (sd) 61 (9) 60 (9) .08 58 (9) 58 (9) .83
Smoking Status: N (%)
Never 36 (10) 194 (51) 8 (8) 48 (47)
Former 132 (36) 119 (32) 24 (25) 31 (30)
Current 195 (54) 64 (17) <.0001 63 (66) 23 (23) <.0001
Pack-years among Smokers: Mean (sd) 51 (30) 26 (23) <.0001 30 (22) 23 (23) .07
History of COPD1: N (%)
No 242 (66) 326 (86) 72 (76) 90 (87)
Yes 122 (34) 54 (14) <.0001 23 (24) 13 (13) .03
Family History of Lung Cancer: N (%)
No 277 (76) 334 (88) 67 (71) 92 (89)
Yes 87 (24) 46 (12) <.0001 28 (29) 11 (11) .0009
Regular Adult Aspirin Use: N (%)
Never 272 (76) 280 (74) 77 (82) 78 (76)
Ever 86 (24) 100 (26) .47 17 (18) 24 (24) .35
Years of Education: Mean (sd) 13 (2) 14 (3) <.0001 12 (3) 13 (2) .03
BMI2: Mean (sd) 26 (6) 29 (7) <.0001 27 (7) 32 (8) <.0001
1 Chronic obstructive pulmonary disease including chronic obstructive lung disease, emphysema, and chronic bronchitis. 2Body mass index = weight and
height in kg/m2.
subsequent analyses were conducted separately by race. The
minor allele of TERT-rs2075786 was associated with a three-
fold increased risk of lung cancer among African American
(OR 3.04; 95% CI 1.26–7.30) but not Caucasian women.
TERT-rs2853677 G allele was associated with increased risk
of NSCLC among both Caucasian and African American
women. The G allele of TERT-rs2735940 was associated with
a decreased risk of lung cancer among African Americans
(OR 0.38; 95% CI 0.17–0.85) but not among Caucasians
(OR 0.99; 95% CI 0.66–1.49). Six GHR polymorphisms
were associated with an approximately 50% increased risk
of NSCLC among Caucasian, but not African American,
women. One SEPP1 SNP, rs6413428, increased lung cancer
risk among Caucasian women only but was in HWD among
African American controls. None of the SNPs in AHRR,
SLC6A3, MTRR, or AMACR were associated with risk of
NSCLC in either Caucasian or African American women
on single SNP analysis. −log10(P-value) was plotted by
chromosome position for associations between single SNPs
and lung cancer risk among Caucasians (Figure 1(a))a n d
African Americans (Figure 1(b)) using P-values unadjusted
for multiple comparisons. On whole-gene association analy-
sis, AMACR, GHR,a n dTERT were signiﬁcantly associated
with NSCLC risk in African American women even after
adjustment for multiple comparisons (P-value =.02,.03,
and.02, resp.). The associations between TERT, GHR,a n d
SEPP1 and lung cancer risk approached signiﬁcance among
Caucasians after adjustment for multiple comparisons (all
three P-values =.06). Analysis of relationships between
chromosome 5p SNPs and NSCLC risk by race under
recessive, genotypic, and log additive models also indicated
associations between SLC6A3-rs6347 and GHR-rs2972395
SNPs and a decreased risk of NSCLC among African
Americanwomenunderarecessivemodel(seeSupplemental
Material online at doi:10.1155/2009/242151). Associations
between SNPs and lung cancer risk did not diﬀer when
participantswith>10%genotypedatamissingwereexcluded
and data were reclustered (data not shown).
3.4. Random Forest Analysis. Not surprisingly, smoking
pack-year history and family history of lung cancer were the
most important variables for both racial groups (Table 3).
The importance of GHR polymorphisms among Cau-
casian women and TERT SNPs among African American
women was reinforced through the random forest analysis
results. Among African Americans, other important classi-
ﬁers of lung cancer case-control status included AMACR-
rs840409, adult aspirin use, and three GHR polymorphisms
(rs1858136, rs2972780, and rs7712701). Out of bag estimates
of error rates were 24% and 28% for Caucasians and African
Americans, respectively.
3.5. Chromosome 5p SNPs, Smoking, and Risk of NSCLC.
Associations between polymorphisms in TERT (rs2853677),
GHR (rs6873545, rs6897530, rs6179, and rs2972780), SEPP1
(rs6413428) and lung cancer risk were observed among
Caucasian women who were ever smokers but not among
never smokers (Table 4).
3.6. Chromosome 5p SNPs, and Risk of Adenocarcinoma
of the Lung. When analyses were restricted to analyzingJournal of Cancer Epidemiology 5
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Table 3: Top ten variables classifying NSCLC case-control status by race on random forest analysis
Caucasians African Americans
Variable Mean decrease
accuracy Variable Mean decrease
accuracy
Smoking
Pack-year History 1.27 Smoking
Pack-year History 2.01
COPD History 0.48 Family History of
Lung Cancer 0.84
Family History of
Lung Cancer 0.26 rs2735940-TERT 0.39
rs7735889-GHR 0.26 rs2853690-TERT 0.32
rs2972780-GHR 0.24 rs1858136-GHR 0.28
rs33939197-GHR 0.24 rs840409-AMACR 0.28
rs2940944-GHR 0.20 rs2972780-GHR 0.27
rs2940913-GHR 0.20 Regular Adult
Aspirin Use 0.26
rs2972395-GHR 0.19 rs2853677-TERT 0.25
rs6878512-GHR 0.19 rs7712701-GHR 0.24
Table 4: Chromosome 5p SNPs and NSCLC Risk by Smoking History (Never/Ever) among Caucasians1
.
Never smokers Ever smokers
SNP Ncases Ncontrols OR2 (95% CI) Ncases Ncontrols OR3 (95% CI)
rs2853677-TERT AA 5 61 1.00 76 60 1.00
AG/GG 29 132 2.43 (0.88–6.72) 247 125 1.62 (1.01–2.60)
rs6873545-GHR TT 17 100 1.00 159 104 1.00
TC/CC 19 92 0.99 (0.47–2.09) 168 82 1.79 (1.16–2.78)
rs6897530-GHR TT 17 103 1.00 158 105 1.00
TC/CC 19 90 1.02 (0.48–2.16) 169 81 1.80 (1.16–2.78)
rs6179-GHR GG 18 106 1.00 154 101 1.00
GA/AA 18 88 0.93 (0.44–1.96) 174 85 1.70 (1.10–2.62)
rs2972780-GHR CC 17 108 1.00 156 104 1.00
CT/TT 19 86 1.09 (0.52–2.31) 172 82 1.67 (1.08–2.58)
rs6413428-SEPP1 AA 17 116 1.00 165 108 1.00
AG/GG 19 77 1.33 (0.63–2.83) 162 78 1.64 (1.06–2.54)
1 Only SNPs associated with NSCLC risk among either never smokers or ever smokers are displayed. 2Adjusted for age at diagnosis/interview, years of
education, family history of lung cancer, history of COPD, adult aspirin use, and BMI. 3Adjusted for age at diagnosis/interview, smoking pack-year history,
years of education, family history of lung cancer, history of COPD, adult aspirin use, and BMI.
associations with risk of adenocarcinoma of the lung,
the results on logistic regression analysis did not change in
terms of direction or magnitude for Caucasians or African
Americans.
3.7. Linkage Disequilibrium, Haplotypes and Risk of NSCLC.
For TERT region genes, only one pair of SNPs had an r2
value >0.30, rs2853677 and rs2735940, among Caucasian
controls. No linkage disequilibrium was identiﬁed in African
American controls. PLINK identiﬁed the TERT haplotype
rs2853690-rs2075786-rs2853677-rs2735940. Among Cau-
casians, the A-G-A-G (OR 0.59; 95% CI 0.37–0.94) and
G-G-A-A (OR 0.41; 95% CI 0.19–0.88) haplotypes were
associated with lung cancer on logistic regression analysis;
however, these associations were not statistically signiﬁcant
after correcting for multiple comparisons (each P-value =
0.14).
3.8. LD Patterns in GHR SNPs Also Diﬀered by Race among
Controls. Among Caucasian controls, SNPs in this gene were
more tightly linked than in African Americans as evident by
the magnitude of r2 values and the number of SNP pairs
with r2 values >0.30. Not surprisingly, an area of tight LD
among controls included polymorphisms in the region that
were all associated with risk of NSCLC among Caucasian
but not African American women on logistic regression
analysis. None of the GHR rs6873545-rs4451056-rs6878512-
rs6897530-rs6179-rs2972780 haplotypes were associated
with NSCLC risk among Caucasians or African Americans.
3.9. SIFT Results. Of the ﬁve nonsynonymous SNPs ana-
lyzed in this study, SIFT scores were returned for four
(rs10380-MTRR, rs34677-AMACR, rs2278008-AMACR,a n d
rs2287939-AMACR). Two of these polymorphisms, rs103808 Journal of Cancer Epidemiology
and rs34677, were considered to result in damaging amino
acid substitutions according to our criterion (prediction
score (median sequence IC value): 0.02 (1.85) and 0.09
(2.02), resp.).
4. Discussion
TERT region SNPs, rs2075786, rs2853677, and rs273940,
were associated with risk of NSCLC among African Amer-
icans, whereas only rs2853677-TERT was associated with
risk of lung cancer among Caucasians. A region of six GHR
polymorphisms in LD among Caucasians was associated
with risk of lung cancer among Caucasians but not African
Americans. Random forest analysis reinforced the associ-
ations of TERT and GHR SNPs with lung cancer among
African Americans and Caucasians. SEPP1-rs6413428 was
marginally associated with NSCLC risk among Caucasian
women only. One AMACR polymorphism, rs840409, was
identiﬁed based on random forest analysis as associated
with lung cancer among African Americans. On whole
gene association analysis, TERT, GHR,a n dAMACR were
associated with NSCLC among African American women.
4.1. TERT. The association between TERT polymorphisms
and lung cancer has been observed in at least two other
studies in Caucasian populations [2, 3]. Both of these
genome wide association studies identiﬁed rs401681 in the
nearby CRR9 (aka, CLPTM1L) gene as being associated with
lung cancer risk. Wang et al. (2008) also identiﬁed the TERT
SNP rs4975616 [2]. Neither rs401681 nor rs4975616 is in
LD with rs1801075 among the CEU (r2 = 0.22 and 0.23,
resp.) or YRI (r2 = 0.14 and 0.06, resp.) populations, which
was not associated with NSCLC in our study among either
Caucasian or African American women. The associations
detectedinourstudywerewithTERT SNPsfurtherupstream
of this region (Figures 1(a) and 1(b)). Relationships between
TERT polymorphisms and disease susceptibility have been
previously reported for breast cancer among people with a
family history [27] and for idiopathic pulmonary ﬁbrosis
[28], suggesting that this gene may be of interest in both
pulmonary disease and solid tumor development. Moreover,
the whole gene association analysis results underscore the
importance of any modiﬁcation in the TERT gene especially
among African Americans.
4.2. GHR. The association between GHR and cancer risk
has only recently been explored [17, 18, 29]. Two studies
examined the relationship between the Pro495Thr SNP
(rs6183) and risk of lung cancer among Chinese and British
Caucasian populations [17, 18]. Increased risk was observed
in relation to squamous cell or small cell lung cancer but not
to adenocarcinoma of the lung. Rudd et al. [18]r e p o r t e d
an increased risk of lung cancer under a dominant model
[18]. However, the minor allele frequency for this locus
was only 0.001, and the upper limit of the 95% CI was
inﬁnity, limiting valid conclusions about the magnitude of
the associated risk. Cao et al. [17] observed an increased risk
of lung cancer among current smokers and among people
with a family history of cancer [17]. This polymorphism lies
in linkage disequilibrium among the CEU population with
SNPs associated with an approximately 50% increased risk
of NSCLC among Caucasians in our study (ex: rs6873545,
rs4451056, and rs6878512). In combination with the two
previous studies, these results suggest that the disease marker
lies somewhere within this region on GHR. Whether that
disease marker is rs6183, which SIFT predicts to have a
damaging eﬀect on protein function, or another marker in
the region remains to be determined. Further research into
the role of GHR in NSCLC development is warranted.
4.3. SEPP1. SEPP1 codes for a selonoprotein that binds 40%
to 60% of circulating selenium in the plasma and functions
as a transport protein and as a facilitator of intracellular
binding of selenium. Selenium treatment has been shown
to be associated with a signiﬁcant decrease in the incidence
of lung cancer among people with low baseline selenium
concentrations (HR 0.42; 95% CI 0.18–0.96) [30]. While the
SNP identiﬁed in our study, rs6413428, has not been asso-
ciated with cancer risk in previous studies, SEPP1 SNPs in
other regions of the gene have been associated with advanced
distal colorectal adenoma risk and prostate cancer [31, 32].
Previously studied SNPs are not in linkage disequilibrium
with the SNP identiﬁed in our study; therefore, rs6413428
may represent a SEPP1 region with a relationship unique to
lung cancer risk.
4.4. AMACR. AMACR codes for α-methylacyl-CoA race-
mase (AMACR), which plays a role in branched chain fatty
acid and bile acid intermediate metabolism. It is expressed
in approximately 14% to 56% of lung cancers depending on
tumor histology; however, no study has compared AMACR
expression in lung tumor and nontumor tissue [33–35].
The bulk of the research examining AMACR variants and
risk of cancer has focused on prostate cancer [36–38]. All
but two of the eight SNPs included in these studies were
also analyzed in our study, which identiﬁed one AMACR
SNP rs840409 as being associated with NSCLC among
African American women on random forest analysis and
on whole gene association analysis. This SNP is in strong
linkage disequilibrium with rs34677 (r2 = 0.80 and 1.00
among the CEU and YRI populations, resp.), which has been
associated with a protective eﬀect against prostate cancer in a
predominantly nonHispanic Caucasian population. rs34677
encodes a glutamine to histadine amino acid substitution,
which is not tolerated according to SIFT analysis (prediction
score0.09;mediansequenceIC2.02)[36].Whetherrs840409
orrs34677isassociatedwithfamiliallungcancer,asobserved
in prostate cancer [38], remains to be determined.
4.5. Chromosome 5p SNPs, Smoking, and NSCLC Risk. At
least one study has examined interactions between SNPs
in chromosome 5p genes and smoking in association with
lung cancer risk [17]. When Cao et al. (2008) analyzed
interactions between smoking and the GHR Thr495Pro poly-
morphism through multifactor dimensionality reduction
(MDR), they found a relationship between squamous cellJournal of Cancer Epidemiology 9
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Figure 1: (a) Associations between chromosome 5p SNPs and NSCLC risk among Caucasians by chromosome position. Blue markers
signify SNPs examined in our study. Pink markers indicate associations between rs401681 and lung cancer risk identiﬁed in the Rafner et
al. (2009) and Wang et al. (2008) papers [2, 3]. The region of 5p surrounding rs401681 is expanded in the ﬁgure. Pink and blue rectangles
surround rs401681 in CLPTM1L (aka CRR9) and the region of SNPs included in our study in TERT, respectively. (b) Associations between
chromosome 5p SNPs and NSCLC risk among African Americans by chromosome position. Blue markers signify SNPs examined in our
study.10 Journal of Cancer Epidemiology
carcinoma, but not adenocarcionma, of the lung among
current smokers and concluded that GHR signaling is
involved with smoking metabolism. While our sample
included mostly adenocarcinomas (74%), we still observed
associations between lung cancer and GHR polymorphisms
only among ever smokers. Also identiﬁed as having a
diﬀerential association with NSCLC risk based on smoking
history, SEPP1 may have a role in uptake of the antioxidant
selenium, which currently is being tested for its eﬃcacy
in preventing lung cancer recurrence through the SELECT
trial (Selenium and vitamin E Cancer prevention Trial).
Polymorphisms that either increase GHR activity or decrease
selenium transport may enhance a smoker’s risk of lung
cancer regardless of histology.
Surprisingly, genes associated with smoking addiction
and the impact of cigarette smoke were not related to
lung cancer risk in our study. The dopamine transporter
gene, SLC6A3, has been associated with cigarette smoking
addiction in previous studies. At least one study by Campa
et al. (2007) reported that a polymorphism in the dopamine
transporter gene SLC6A3, rs6413429, that confers decreased
dopamine bioavailability was associated with increased
NSCLC risk even after controlling for smoking history
suggesting that the role of this gene in lung cancer risk may
involve other molecular signaling mechanisms [14]. In our
study, this SNP was not associated with NSCLC risk among
Caucasian women as a whole, Caucasian never smokers, or
Caucasianeversmokers(datanotshown).Theseassociations
were not analyzed among African Americans in our study
because the minor allele frequency among African American
controls was <5%.
Another gene associated with the response to cigarette
smoke compounds, the aryl hydrocarbon receptor repressor
gene (AHRR) was not associated with NSCLC risk in our
study. AHRR functions as a tumor suppressor in lung
cell lines and represses activity of the aryl hydrocarbon
receptor (AHR), a transcription factor mediating the eﬀects
of cigarette smoke contaminants by inducing CYP1A1
expression [39, 40]. At least two previous studies in Japanese
and French populations did not ﬁnd an association between
AHRR polymorphisms and lung cancer risk [41, 42]. The
lack of association between SNPs in these smoking related
genes and lung cancer risk suggests that modiﬁcations in
multiple smoking and cigarette smoke response genes, and
not any single gene, may act in concert to aﬀect lung cancer
risk.
4.6. Logistic Regression versus Random Forest Analysis. Logis-
tic regression and random forest analysis were used in
this study to examine associations between risk factors and
disease.Whilelogisticregressionprovideseasilyinterpretable
estimates of the probability of disease, SNPs are considered
one at a time in single SNP models. Random forest analysis
compliments logistic regression by assessing the importance
ofasingleSNPtakingintoconsiderationotherSNPsandrisk
factors. Furthermore, the two methods diﬀer in that logistic
regression is linear and random forest is nonlinear with a
bagging algorithm. Thus, the two approaches may identify
diﬀerent associations.
4.7. Limitations. Because no proxy interviews were con-
d u c t e d ,w o m e nh a dt ob ew e l le n o u g ht oc o m p l e t ea ni n -
person interview. As previously reported, nonparticipating
cases were slightly older, were more likely to be diagnosed
at a distant stage, and had signiﬁcantly shorter survival
times than participating cases [20]. In addition, most cases
had adenocarcinoma of the lung; so results obtained in
this study may not be generalizable to all lung cancers.
Additionally, for some SNPs, the number of subjects with
homozygous variant genotypes may have been too few
for testing associations under recessive, genotypic, or log-
additive models. The assumption of a dominant genetic
model in our analyses may not be the most appropriate.
Results were no longer statistically signiﬁcant after P-values
were adjusted for multiple comparisons, and some ﬁndings
may be false positives. However, corrections for multiple
testing were made through the FDR method, which does not
take into account the dependency of the tests between SNPs
in the same gene according to linkage disequilibrium, an
important point given the linkage disequilibrium observed.
The numbers of never smokers who developed NSCLC
and of African Americans included in this study were too
small for analysis by smoking history and history of COPD.
The small number of never smokers raises the question of
whether the lack of associations between 5p region SNPs
and NSCLC among never smokers was a result of inadequate
power, especially for rs2853677-TERT. Furthermore, all
African Americans were combined into a single group
regardless of genetically determine ancestry. Finally, these
analyses need to be repeated in studies involving larger
sample sizes, especially of African Americans, to determine
whether these ﬁndings can be replicated.
5. Conclusions
Because allelic frequencies and linkage disequilibrium pat-
terns in chromosome 5p genes diﬀer by self-reported race,
analyses of genetic associations with cancer risk should take
into account race. Diﬀerential associations between SNPs
and haplotypes in this region and NSCLC risk by race also
suggest that potential mechanisms underlying susceptibil-
ity to lung tumorigenesis may diﬀer by race. Moreover,
our results indicate that potential chemopreventive targets
among Caucasian smokers include TERT, GHR,a n dSEPP1.
There is a need for further studies with a larger number of
AfricanAmericanstoascertainwhetherassociationsbetween
thesethreegenesandlungcancerriskalsomaybegeneralized
to African American smokers.
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